Public dataset

Recorded source agreement and disagreement

Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.

What this does not mean: agree can mean only that sources print the same normalized reading; it is not clinical-context equivalence, independent replication, or proof. differ requires matching structured context and disjoint comparable values. not_comparable and insufficient_context are not disagreement.

Public rows: 1,681
Generated: 2026-09-12
Schema version: source-consensus/2

Coverage

What this run contains

Compared medicine fields: 1,681
Agree: 1,282
Differ: 0
Not comparable: 12
Insufficient context: 387
Fields represented: 5; bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution

Method

How the rows were made

Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.

Limits

Read these before using a row

Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
Only the recorded fields and source documents in this snapshot are compared.
A source count is the number of retained source records in the row, not a count of independent experiments.

Provenance

Source examples

abacavir · bioavailability · agree

15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b

The geometric mean absolute bioavailability of the tablet was 83%.

alemtuzumab · volumeOfDistribution · not_comparable

2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0

Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).

abiraterone · halfLife · insufficient_context

31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a

Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.

Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

Field	Type	Meaning
medicineSlug	string	Stable RNAWiki medicine route key.
field	string	Recorded pharmacokinetic field being compared.
comparisonState	string	agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero.
comparisonReasons	string[]	Deterministic codes explaining the state.
documentsExamined	number	Recorded source documents considered for the field.
sourceCount	number	Recorded source readings represented.
agreementRate	number	Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability.
readings	consensus-reading[]	Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt.

Reader

Search and filter the rows

Showing 391–400 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

Projected row 391
Medicine slug
denosumab-bmwo
Compared field
halfLife
Comparison state
insufficient_context
Reason codes
- STRUCTURED_CONTEXT_MISSING
Documents examined
4
Source count
4
Agreement rate
0.5
Recorded readings
1. 25.4 days
  Numeric value
  Not parsed
  Unit
  Not recorded
  Source records
  2
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 2 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:10b9eea3-bf70-4ff3-a0b9-54248cbfd156 (opens source in a new tab)
  Denosumab-Bmwo label
  Version not recorded · Effective date not recorded
  Elimination Serum denosumab concentrations declined over a period of 4 to 5 months with a mean half-life of 25.4 days (SD = 8.5 days; n = 46).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:7a449553-105c-46a1-bb72-849d8f5b81bd (opens source in a new tab)
  Denosumab-Bmwo label
  Version not recorded · Effective date not recorded
  Elimination Serum denosumab concentrations declined over a period of 4 to 5 months with a mean half-life of 25.4 days (SD = 8.5 days; n = 46).
2. 28 days
  Numeric value
  Not parsed
  Unit
  Not recorded
  Source records
  2
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 2 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:c5a5d750-80be-49cd-b4a6-c8a815956059 (opens source in a new tab)
  Denosumab-Bmwo label
  Version not recorded · Effective date not recorded
  The mean elimination half-life was 28 days.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:d378622d-3a13-4918-ae18-3375cd10d270 (opens source in a new tab)
  Denosumab-Bmwo label
  Version not recorded · Effective date not recorded
  The mean elimination half-life was 28 days.
Projected row 392
Medicine slug
denosumab-bmwo
Compared field
volumeOfDistribution
Comparison state
agree
Reason codes
- COMPATIBLE_VALUES_OVERLAP
Documents examined
4
Source count
2
Agreement rate
1
Recorded readings
1. 5.2 L
  Numeric value
  5.2
  Unit
  L
  Source records
  2
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 2 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:10b9eea3-bf70-4ff3-a0b9-54248cbfd156 (opens source in a new tab)
  Denosumab-Bmwo label
  Version not recorded · Effective date not recorded
  Distribution The mean volume of distribution for denosumab was 5.2 L (SD = 1.7 L).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:7a449553-105c-46a1-bb72-849d8f5b81bd (opens source in a new tab)
  Denosumab-Bmwo label
  Version not recorded · Effective date not recorded
  Distribution The mean volume of distribution for denosumab was 5.2 L (SD = 1.7 L).
Projected row 393
Medicine slug
denosumab-desu
Compared field
halfLife
Comparison state
insufficient_context
Reason codes
- STRUCTURED_CONTEXT_MISSING
Documents examined
2
Source count
2
Agreement rate
0.5
Recorded readings
1. 25.4 days
  Numeric value
  Not parsed
  Unit
  Not recorded
  Source records
  1
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 1 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:5f3be096-5100-4d0e-b765-481bbb2672e1 (opens source in a new tab)
  Denosumab-Desu label
  Version not recorded · Effective date not recorded
  Elimination Serum denosumab concentrations declined over a period of 4 to 5 months with a mean half-life of 25.4 days (SD=8.5 days; n=46) A population pharmacokinetic analysis was performed to evaluate the effects of demographic characteristics.
2. 28 days
  Numeric value
  Not parsed
  Unit
  Not recorded
  Source records
  1
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 1 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:e15dfe74-1575-4a2a-895e-323c05613362 (opens source in a new tab)
  Denosumab-Desu label
  Version not recorded · Effective date not recorded
  The mean elimination half-life was 28 days.
Projected row 394
Medicine slug
denosumab-kyqq
Compared field
halfLife
Comparison state
insufficient_context
Reason codes
- STRUCTURED_CONTEXT_MISSING
Documents examined
2
Source count
2
Agreement rate
0.5
Recorded readings
1. 25.4 days
  Numeric value
  Not parsed
  Unit
  Not recorded
  Source records
  1
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 1 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:1e5e8c88-3c65-3076-e44b-02d92c2d343d (opens source in a new tab)
  Denosumab-Kyqq label
  Version not recorded · Effective date not recorded
  Elimination Serum denosumab concentrations declined over a period of 4 to 5 months with a mean half-life of 25.4 days (SD = 8.5 days; n = 46).
2. 28 days
  Numeric value
  Not parsed
  Unit
  Not recorded
  Source records
  1
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 1 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:547cb095-f7f5-f933-75ce-5e6abf2ad5bc (opens source in a new tab)
  Denosumab-Kyqq label
  Version not recorded · Effective date not recorded
  The mean elimination half-life was 28 days.
Projected row 395
Medicine slug
denosumab-mobz
Compared field
halfLife
Comparison state
insufficient_context
Reason codes
- STRUCTURED_CONTEXT_MISSING
Documents examined
2
Source count
2
Agreement rate
0.5
Recorded readings
1. 25.4 days
  Numeric value
  Not parsed
  Unit
  Not recorded
  Source records
  1
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 1 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:29140df2-24a3-4a6f-a8e3-065521448d61 (opens source in a new tab)
  Denosumab-Mobz label
  Version not recorded · Effective date not recorded
  Elimination Serum denosumab concentrations declined over a period of 4 to 5 months with a mean half-life of 25.4 days (SD = 8.5 days; n = 46).
2. 28 days
  Numeric value
  Not parsed
  Unit
  Not recorded
  Source records
  1
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 1 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:f040a245-1be4-4962-a8b7-a13ee7fac707 (opens source in a new tab)
  Denosumab-Mobz label
  Version not recorded · Effective date not recorded
  The mean elimination half-life was 28 days.
Projected row 396
Medicine slug
denosumab-qbde
Compared field
halfLife
Comparison state
insufficient_context
Reason codes
- STRUCTURED_CONTEXT_MISSING
Documents examined
2
Source count
2
Agreement rate
0.5
Recorded readings
1. 25.4 days
  Numeric value
  Not parsed
  Unit
  Not recorded
  Source records
  1
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 1 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:815d3ba4-27a1-4a06-925a-a87f35442bdb (opens source in a new tab)
  Denosumab-Qbde label
  Version not recorded · Effective date not recorded
  Elimination Serum denosumab concentrations declined over a period of 4 to 5 months with a mean half-life of 25.4 days (SD = 8.5 days; n = 46).
2. 28 days
  Numeric value
  Not parsed
  Unit
  Not recorded
  Source records
  1
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 1 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:a48a3a33-6b0e-4cf4-8786-8f662d6ee77b (opens source in a new tab)
  Denosumab-Qbde label
  Version not recorded · Effective date not recorded
  The mean elimination half-life was 28 days.
Projected row 397
Medicine slug
desloratadine
Compared field
halfLife
Comparison state
agree
Reason codes
- COMPATIBLE_VALUES_OVERLAP
Documents examined
13
Source count
13
Agreement rate
1
Recorded readings
1. 50 hours
  Numeric value
  50
  Unit
  hours
  Source records
  13
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 13 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:4d094001-b85a-47b3-bc67-a46660384ece (opens source in a new tab)
  Desloratadine label
  Version not recorded · Effective date not recorded
  In pharmacokinetic studies (n=3748), approximately 6% of subjects were poor metabolizers of desloratadine (defined as a subject with an AUC ratio of 3-hydroxydesloratadine to desloratadine less than 0.1, or a subject with a desloratadine half-life exceeding 50 hours).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:cf7f838b-4595-4c81-97b9-e1594347e1bd (opens source in a new tab)
  Desloratadine label
  Version not recorded · Effective date not recorded
  In pharmacokinetic studies (n=3748), approximately 6% of subjects were poor metabolizers of desloratadine (defined as a subject with an AUC ratio of 3-hydroxydesloratadine to desloratadine less than 0.1, or a subject with a desloratadine half-life exceeding 50 hours).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:e5d1f465-e436-b4fd-d351-07a7b2acb440 (opens source in a new tab)
  Desloratadine label
  Version not recorded · Effective date not recorded
  In pharmacokinetic studies (n=3748), approximately 6% of subjects were poor metabolizers of desloratadine (defined as a subject with an AUC ratio of 3-hydroxydesloratadine to desloratadine less than 0.1, or a subject with a desloratadine half-life exceeding 50 hours).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:f84c8de3-a7d3-4e8b-bfb6-04259e79450a (opens source in a new tab)
  Desloratadine label
  Version not recorded · Effective date not recorded
  In pharmacokinetic studies (n=3748), approximately 6% of subjects were poor metabolizers of desloratadine (defined as a subject with an AUC ratio of 3-hydroxydesloratadine to desloratadine less than 0.1, or a subject with a desloratadine half-life exceeding 50 hours).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:e4db30a5-48e5-4fe3-8793-30b6866f87c1 (opens source in a new tab)
  Desloratadine label
  Version not recorded · Effective date not recorded
  In pharmacokinetic studies (n = 3748), approximately 6% of subjects were poor metabolizers of desloratadine (defined as a subject with an AUC ratio of 3-hydroxydesloratadine to desloratadine less than 0.1, or a subject with a desloratadine half-life exceeding 50 hours).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:0fe374d0-c14b-4102-b568-eb79165fc7ef (opens source in a new tab)
  Desloratadine label
  Version not recorded · Effective date not recorded
  In pharmacokinetic studies (n=3748), approximately 6% of subjects were poor metabolizers of desloratadine (defined as a subject with an AUC ratio of 3-hydroxydesloratadine to desloratadine less than 0.1, or a subject with a desloratadine half-life exceeding 50 hours).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:41d5e0d4-6188-847b-e063-6294a90a2e2f (opens source in a new tab)
  Desloratadine label
  Version not recorded · Effective date not recorded
  In pharmacokinetic studies (n=3,748), approximately 6% of subjects were poor metabolizers of desloratadine (defined as a subject with an AUC ratio of 3-hydroxydesloratadine to desloratadine less than 0.1, or a subject with a desloratadine half-life exceeding 50 hours).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:36307c2b-6b6a-46a9-9fe4-1798fc72e7b8 (opens source in a new tab)
  Desloratadine label
  Version not recorded · Effective date not recorded
  In pharmacokinetic studies (n=3748), approximately 6% of subjects were poor metabolizers of desloratadine (defined as a subject with an AUC ratio of 3-hydroxydesloratadine to desloratadine less than 0.1, or a subject with a desloratadine half-life exceeding 50 hours).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:21174c0f-9204-4c75-b6e6-2f9ada5b535d (opens source in a new tab)
  Desloratadine label
  Version not recorded · Effective date not recorded
  In pharmacokinetic studies (n=3748), approximately 6% of subjects were poor metabolizers of desloratadine (defined as a subject with an AUC ratio of 3-hydroxydesloratadine to desloratadine less than 0.1, or a subject with a desloratadine half-life exceeding 50 hours).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:a3b61ab9-ec20-4831-b69a-fcd913fce540 (opens source in a new tab)
  Desloratadine label
  Version not recorded · Effective date not recorded
  In pharmacokinetic studies (n=3748), approximately 6% of subjects were poor metabolizers of desloratadine (defined as a subject with an AUC ratio of 3-hydroxydesloratadine to desloratadine less than 0.1, or a subject with a desloratadine half-life exceeding 50 hours).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:2a90b899-7746-43dc-ac8a-e754428eb30c (opens source in a new tab)
  Desloratadine label
  Version not recorded · Effective date not recorded
  In pharmacokinetic studies (n=3748), approximately 6% of subjects were poor metabolizers of desloratadine (defined as a subject with an AUC ratio of 3-hydroxydesloratadine to desloratadine less than 0.1, or a subject with a desloratadine half-life exceeding 50 hours).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:69b9635b-c790-4316-a790-67b0f5512b72 (opens source in a new tab)
  Desloratadine label
  Version not recorded · Effective date not recorded
  In pharmacokinetic studies (n=3748), approximately 6% of subjects were poor metabolizers of desloratadine (defined as a subject with an AUC ratio of 3-hydroxydesloratadine to desloratadine less than 0.1, or a subject with a desloratadine half-life exceeding 50 hours).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:c671342e-69a2-4ca5-abc2-8166ed4240d4 (opens source in a new tab)
  Desloratadine label
  Version not recorded · Effective date not recorded
  In pharmacokinetic studies (n=3748), approximately 6% of subjects were poor metabolizers of desloratadine (defined as a subject with an AUC ratio of 3-hydroxydesloratadine to desloratadine less than 0.1, or a subject with a desloratadine half-life exceeding 50 hours).
Projected row 398
Medicine slug
desloratadine
Compared field
tMax
Comparison state
agree
Reason codes
- COMPATIBLE_VALUES_OVERLAP
Documents examined
13
Source count
12
Agreement rate
1
Recorded readings
1. 3 hours
  Numeric value
  3
  Unit
  hours
  Source records
  12
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 12 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:4d094001-b85a-47b3-bc67-a46660384ece (opens source in a new tab)
  Desloratadine label
  Version not recorded · Effective date not recorded
  etics Absorption Following oral administration of a desloratadine 5 mg tablet once daily for 10 days to normal healthy volunteers, the mean time to maximum plasma concentrations (T max ) occurred at approximately 3 hours post dose and mean steady state peak plasma concentrations (C max ) and AUC of 4 ng/mL and 56.9 ng·hr/mL were observed, respectively.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:cf7f838b-4595-4c81-97b9-e1594347e1bd (opens source in a new tab)
  Desloratadine label
  Version not recorded · Effective date not recorded
  12.3 Pharmacokinetics Absorption Following oral administration of a desloratadine 5 mg tablet once daily for 10 days to normal healthy volunteers, the mean time to maximum plasma concentrations (T max ) occurred at approximately 3 hours post dose and mean steady state peak plasma concentrations (C max ) and AUC of 4 ng/mL and 56.9 ng∙hr/mL were observed, respectively.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:f84c8de3-a7d3-4e8b-bfb6-04259e79450a (opens source in a new tab)
  Desloratadine label
  Version not recorded · Effective date not recorded
  12.3 Pharmacokinetics Absorption Following oral administration of a desloratadine 5 mg tablet once daily for 10 days to normal healthy volunteers, the mean time to maximum plasma concentrations (T max ) occurred at approximately 3 hours post dose and mean steady state peak plasma concentrations (C max ) and AUC of 4 ng/mL and 56.9 ng∙hr/mL were observed, respectively.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:e4db30a5-48e5-4fe3-8793-30b6866f87c1 (opens source in a new tab)
  Desloratadine label
  Version not recorded · Effective date not recorded
  12.3 Pharmacokinetics Absorption Following oral administration of a desloratadine 5 mg tablet once daily for 10 days to normal healthy volunteers, the mean time to maximum plasma concentrations (T max ) occurred at approximately 3 hours post dose and mean steady state peak plasma concentrations (C max ) and AUC of 4 ng/mL and 56.9 ng•hr/mL were observed, respectively.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:0fe374d0-c14b-4102-b568-eb79165fc7ef (opens source in a new tab)
  Desloratadine label
  Version not recorded · Effective date not recorded
  12.3 Pharmacokinetics Absorption Following oral administration of a desloratadine 5 mg tablet once daily for 10 days to normal healthy volunteers, the mean time to maximum plasma concentrations (T max ) occurred at approximately 3 hours post dose and mean steady state peak plasma concentrations (C max ) and AUC of 4 ng/mL and 56.9 ng∙hr/mL were observed, respectively.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:41d5e0d4-6188-847b-e063-6294a90a2e2f (opens source in a new tab)
  Desloratadine label
  Version not recorded · Effective date not recorded
  etics Absorption: Following oral administration of a desloratadine 5 mg tablet once daily for 10 days to normal healthy volunteers, the mean time to maximum plasma concentrations (Tmax) occurred at approximately 3 hours post dose and mean steady state peak plasma concentrations (Cmax) and AUC of 4 ng/mL and 56.9 ng∙hr/mL were observed, respectively.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:36307c2b-6b6a-46a9-9fe4-1798fc72e7b8 (opens source in a new tab)
  Desloratadine label
  Version not recorded · Effective date not recorded
  12.3 Pharmacokinetics Absorption Following oral administration of a desloratadine 5 mg tablet once daily for 10 days to normal healthy volunteers, the mean time to maximum plasma concentrations (T max ) occurred at approximately 3 hours post dose and mean steady state peak plasma concentrations (C max ) and AUC of 4 ng/mL and 56.9 ng∙hr/mL were observed, respectively.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:21174c0f-9204-4c75-b6e6-2f9ada5b535d (opens source in a new tab)
  Desloratadine label
  Version not recorded · Effective date not recorded
  etics Absorption Following oral administration of a desloratadine 5 mg tablet once daily for 10 days to normal healthy volunteers, the mean time to maximum plasma concentrations (T max ) occurred at approximately 3 hours post dose and mean steady state peak plasma concentrations (C max ) and AUC of 4 ng/mL and 56.9 ng-hr/mL were observed, respectively.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:a3b61ab9-ec20-4831-b69a-fcd913fce540 (opens source in a new tab)
  Desloratadine label
  Version not recorded · Effective date not recorded
  12.3 Pharmacokinetics Absorption Following oral administration of a desloratadine 5 mg tablet once daily for 10 days to normal healthy volunteers, the mean time to maximum plasma concentrations (T max ) occurred at approximately 3 hours post dose and mean steady state peak plasma concentrations (C max ) and AUC of 4 ng/mL and 56.9 ng∙hr/mL were observed, respectively.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:2a90b899-7746-43dc-ac8a-e754428eb30c (opens source in a new tab)
  Desloratadine label
  Version not recorded · Effective date not recorded
  12.3 Pharmacokinetics Absorption Following oral administration of a desloratadine 5 mg tablet once daily for 10 days to normal healthy volunteers, the mean time to maximum plasma concentrations (T max ) occurred at approximately 3 hours post dose and mean steady state peak plasma concentrations (C max ) and AUC of 4 ng/mL and 56.9 ng∙hr/mL were observed, respectively.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:69b9635b-c790-4316-a790-67b0f5512b72 (opens source in a new tab)
  Desloratadine label
  Version not recorded · Effective date not recorded
  12.3 Pharmacokinetics Absorption Following oral administration of a desloratadine 5 mg tablet once daily for 10 days to normal healthy volunteers, the mean time to maximum plasma concentrations (T max ) occurred at approximately 3 hours post dose and mean steady state peak plasma concentrations (C max ) and AUC of 4 ng/mL and 56.9 ng∙hr/mL were observed, respectively.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:c671342e-69a2-4ca5-abc2-8166ed4240d4 (opens source in a new tab)
  Desloratadine label
  Version not recorded · Effective date not recorded
  12.3 Pharmacokinetics Absorption Following oral administration of a desloratadine 5-mg tablet once daily for 10 days to normal healthy volunteers, the mean time to maximum plasma concentrations (T max ) occurred at approximately 3 hours post dose and mean steady state peak plasma concentrations (C max ) and AUC of 4 ng/mL and 56.9 ng∙hr/mL were observed, respectively.
Projected row 399
Medicine slug
desmopressin
Compared field
bioavailability
Comparison state
insufficient_context
Reason codes
- STRUCTURED_CONTEXT_MISSING
Documents examined
43
Source count
14
Agreement rate
0.928571
Recorded readings
1. 5%
  Numeric value
  5
  Unit
  %
  Source records
  13
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 13 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:7a26b415-77cd-4b2f-9c76-fa52d2eb6be6 (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  The bioavailability of desmopressin acetate oral tablets is about 5% compared to intranasal desmopressin acetate, and about 0.16% compared to intravenous desmopressin acetate.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:dc9b0dad-d265-4dff-8191-d936280d85a2 (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  The bioavailability of desmopressin acetate oral tablets is about 5% compared to intranasal desmopressin acetate, and about 0.16% compared to intravenous desmopressin acetate.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:52133714-37d1-458d-9839-f0bd206711ea (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  The bioavailability of Desmopressin Acetate oral tablets is about 5% compared to intranasal desmopressin acetate, and about 0.16% compared to intravenous desmopressin acetate.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:9fba5e90-f541-4588-a5e9-b56198f17e87 (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  The bioavailability of desmopressin acetate oral tablets is about 5% compared to intranasal desmopressin acetate, and about 0.16% compared to intravenous desmopressin acetate.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:72aeef35-c102-b628-0219-9822651887eb (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  The bioavailability of desmopressin acetate oral tablets is about 5% compared to intranasal desmopressin acetate, and about 0.16% compared to intravenous desmopressin acetate.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:0d447b48-3f4b-430e-9e68-d8b9401c002e (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  The bioavailability of desmopressin acetate oral tablets is about 5% compared to intranasal desmopressin acetate, and about 0.16% compared to intravenous desmopressin acetate.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:6d55baa9-2b62-469c-93ae-3909ab249332 (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  The bioavailability of DDAVP oral tablets is about 5% compared to intranasal DDAVP, and about 0.16% compared to intravenous DDAVP.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:24866ad0-94db-46a2-96c0-b362acd0271a (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  The bioavailability of desmopressin acetate oral tablets are about 5% compared to intranasal desmopressin acetate, and about 0.16% compared to intravenous desmopressin acetate.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:f140926e-3201-4b8e-8207-14c560ddb55e (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  The bioavailability of desmopressin acetate oral tablets are about 5% compared to intranasal desmopressin acetate, and about 0.16% compared to intravenous desmopressin acetate.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:f306e2d4-781f-ff8f-e053-2a95a90ad15b (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  The bioavailability of desmopressin acetate oral tablets is about 5% compared to intranasal desmopressin acetate, and about 0.16% compared to intravenous desmopressin acetate.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:e87b6cfd-5677-4398-883d-7ced5dd678ef (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  The bioavailability of desmopressin acetate oral tablets is about 5% compared to intranasal desmopressin acetate, and about 0.16% compared to intravenous desmopressin acetate.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:c04357fd-478a-4909-b098-ae6710be071c (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  The bioavailability of desmopressin acetate oral tablets is about 5% compared to intranasal desmopressin acetate, and about 0.16% compared to intravenous desmopressin acetate.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:c01048e8-d28f-4085-9c37-3d5d48395a77 (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  The bioavailability of Desmopressin Acetate oral tablets is about 5% compared to intranasal desmopressin acetate, and about 0.16% compared to intravenous desmopressin acetate.
2. 0.16%
  Numeric value
  0.16
  Unit
  %
  Source records
  1
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 1 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:4c0e1356-d14f-cfb4-e063-6294a90acd27 (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  Absorption Desmopressin absolute oral bioavailability is 0.16%.
Projected row 400
Medicine slug
desmopressin
Compared field
halfLife
Comparison state
insufficient_context
Reason codes
- STRUCTURED_CONTEXT_MISSING
Documents examined
43
Source count
43
Agreement rate
0.55814
Recorded readings
1. 2.8 hours
  Numeric value
  2.8
  Unit
  hours
  Source records
  24
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 24 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:7f4e5a22-85e8-4c28-9ebf-d6ebc75ad653 (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  12.3 Pharmacokinetics Elimination The geometric mean terminal half-life is 2.8 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:cdec2cc2-4fd9-474e-884f-d0599e40948f (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  12.3 Pharmacokinetics Elimination The geometric mean terminal half-life is 2.8 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:c2e21331-4d54-4fa7-8f0d-31fe23a981aa (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  12.3 Pharmacokinetics Elimination The geometric mean terminal half-life is 2.8 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:1ac423b8-27a6-4cef-4a82-c50bf81b4f49 (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  The terminal half-life was 2.8 hours in subjects with normal renal function, 4.0 hours in mild renal impairment, 6.6 hours in moderate renal impairment and 8.7 hours in severe renal impairment.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:539d7da2-72b8-45f9-836c-4e3351dd488e (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  12.3 Pharmacokinetics Elimination The geometric mean terminal half-life is 2.8 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:60dd8694-58d8-d88e-26f2-f28baa53787e (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  12.3 Pharmacokinetics Elimination The geometric mean terminal half-life is 2.8 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:39381e84-0e87-4731-b725-f0fdf4b5ca2b (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  12.3 Pharmacokinetics Elimination The geometric mean terminal half-life is 2.8 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:40752c75-d09b-4013-9024-442048145b63 (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  12.3 Pharmacokinetics Elimination The geometric mean terminal half-life is 2.8 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:9725ba8e-ac0f-4655-bb98-9ea926142815 (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  12.3 Pharmacokinetics Elimination The geometric mean terminal half-life is 2.8 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:1052a869-b64d-655d-e063-6294a90ad0e2 (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  12.3 Pharmacokinetics Elimination The geometric mean terminal half-life is 2.8 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:8ca799f1-7029-4527-9ab4-7512504bb8e2 (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  The terminal half-life was 2.8 hours in subjects with normal renal function, 4.0 hours in mild renal impairment, 6.6 hours in moderate renal impairment and 8.7 hours in severe renal impairment.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:0d96944d-736d-4b56-b726-d21eacd8bc85 (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  12.3 Pharmacokinetics Elimination The geometric mean terminal half-life is 2.8 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:2a2a6eba-c5bf-4ee4-bb18-c992ae59dce5 (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  12.3 Pharmacokinetics Elimination The geometric mean terminal half-life is 2.8 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:651f6fee-a2c7-431b-8d5d-58b156c72244 (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  12.3 Pharmacokinetics Elimination The geometric mean terminal half-life is 2.8 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:131fd4d8-48ca-4c1f-8165-848dc0a4d511 (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  12.3 Pharmacokinetics Elimination The geometric mean terminal half-life is 2.8 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:d87168b9-f103-4ba5-b0b3-0656d1c81da2 (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  12.3 Pharmacokinetics Elimination The geometric mean terminal half-life is 2.8 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:f5ada39c-20ed-4500-9dce-1e4ab642a358 (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  The geometric mean terminal half-life was 2.8 hours in subjects with normal renal function, and 4, 6.6, and 8.7 hours in subjects with mild, moderate, and severe renal impairment, respectively.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:8034989a-45f5-436b-8b1f-42108ee2a21a (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  The terminal half-life was 2.8 hours in subjects with normal renal function, 4.0 hours in mild renal impairment, 6.6 hours in moderate renal impairment and 8.7 hours in severe renal impairment.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:848d5173-ce26-46bf-b180-7ed13f0233b5 (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  12.3 Pharmacokinetics Elimination The geometric mean terminal half-life is 2.8 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:10b29aa2-274e-4c29-bccd-424bd3761758 (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  12.3 Pharmacokinetics Elimination The geometric mean terminal half-life is 2.8 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:84dbb392-4535-4cbc-af60-75abb494f26e (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  12.3 Pharmacokinetics Elimination The geometric mean terminal half-life is 2.8 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:673cd9ab-b714-49ee-9ce7-c99be605c30e (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  12.3 Pharmacokinetics Elimination The geometric mean terminal half-life is 2.8 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:9fd48eec-aa24-4888-b99f-d409ada958a7 (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  12.3 Pharmacokinetics Elimination The geometric mean terminal half-life is 2.8 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:29df0492-f7ef-47bb-aa67-4ef9e5c2846f (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  12.3 Pharmacokinetics Elimination The geometric mean terminal half-life is 2.8 hours.
2. 3 hours
  Numeric value
  3
  Unit
  hours
  Source records
  15
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 15 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:7a26b415-77cd-4b2f-9c76-fa52d2eb6be6 (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe renal impairment.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:dc9b0dad-d265-4dff-8191-d936280d85a2 (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe renal impairment.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:52133714-37d1-458d-9839-f0bd206711ea (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe renal impairment.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:15179e0c-f677-307f-d1e1-5910de4c212f (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe renal impairment.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:9fba5e90-f541-4588-a5e9-b56198f17e87 (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe renal impairment (See CONTRAINDICATIONS ).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:72aeef35-c102-b628-0219-9822651887eb (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe renal impairment.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:0d447b48-3f4b-430e-9e68-d8b9401c002e (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe renal impairment.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:6d55baa9-2b62-469c-93ae-3909ab249332 (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe renal impairment.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:2dc2cec8-6953-4a33-9356-11534fba1fb8 (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe renal impairment.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:24866ad0-94db-46a2-96c0-b362acd0271a (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe renal impairment.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:f140926e-3201-4b8e-8207-14c560ddb55e (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe renal impairment.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:f306e2d4-781f-ff8f-e053-2a95a90ad15b (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe renal impairment (See CONTRAINDICATIONS ).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:e87b6cfd-5677-4398-883d-7ced5dd678ef (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe renal impairment (see CONTRAINDICATIONS ).
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:c04357fd-478a-4909-b098-ae6710be071c (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe renal impairment.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:c01048e8-d28f-4085-9c37-3d5d48395a77 (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe renal impairment.
3. 8-12 hours
  Numeric value
  8
  Unit
  hours
  Source records
  3
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 3 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:b01c22dc-eecd-11b2-e053-2a95a90a529a (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  The duration of the hemostatic effect depends on the half-life for VIII:C which is about 8-12 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:52680415-52a0-61c2-e063-6294a90ae27e (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  The duration of the hemostatic effect depends on the half-life for VIII:C which is about 8 to 12 hours.
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:b2fad59d-6176-4e09-9fbb-5cdd7f8f1568 (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  The duration of the hemostatic effect depends on the half-life for VIII:C which is about 8-12 hours.
4. 3.6 hours
  Numeric value
  3.6
  Unit
  hours
  Source records
  1
  Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
  Show all 1 source records
  FDA_LABELRetrieved 2026-08-30
  FDA_LABEL:4c0e1356-d14f-cfb4-e063-6294a90acd27 (opens source in a new tab)
  Desmopressin label
  Version not recorded · Effective date not recorded
  Desmopressin estimated elimination half-life is 3.6 hours.

Access

Query or download the projection

View this filtered page as JSON Download up to 200 filtered CSV rows

GET /api/datasets/source-consensus?limit=10&offset=390

Allowed query parameters

q: Case-insensitive text search over the public fields named for this dataset.
state: Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
field: Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
limit / offset: Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy